$CPMV
Mosaic ImmunoEngineering Inc.

2024 Q3 Form 10-Q Financial Statement

#000168316824005676 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $39.60K $60.71K
YoY Change -53.37% -50.5%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $186.4K $274.3K
YoY Change -40.22% -22.19%
Operating Profit -$186.4K -$274.3K
YoY Change -40.22% -22.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$300.00 -$19.42K
YoY Change -98.6% -105.45%
Pretax Income -$186.7K -$293.7K
YoY Change -43.97% -1597.79%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$186.7K -$293.7K
YoY Change -43.97% -1597.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.03 -$0.04
Diluted Earnings Per Share -$0.03 -$0.04
COMMON SHARES
Basic Shares Outstanding 7.242M shares 7.242M shares
Diluted Shares Outstanding 7.236M shares 7.236M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $5.736K $3.734K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.95K $12.28K
YoY Change -86.01% -96.68%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $39.95K $12.28K
Total Long-Term Assets $0.00 $0.00
Total Assets $39.95K $12.28K
YoY Change -86.01% -96.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $143.6K $125.0K
YoY Change 23.36% -4.6%
Accrued Expenses $653.7K $623.6K
YoY Change 0.69% 5.94%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.301M $5.105M
YoY Change 16.02% 17.45%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.301M $5.105M
Total Long-Term Liabilities
Total Liabilities $6.675M $6.461M
YoY Change 13.78% 14.9%
SHAREHOLDERS EQUITY
Retained Earnings -$8.685M -$8.499M
YoY Change 13.97% 16.62%
Common Stock $72.00 $72.00
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.635M -$6.448M
YoY Change
Total Liabilities & Shareholders Equity $39.95K $12.28K
YoY Change -86.01% -96.68%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$186.7K -$293.7K
YoY Change -43.97% -1597.79%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Accretion Expense
AccretionExpense
11473 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-19415 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
372118 usd
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7242137 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7242137 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
72 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2045206 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8498546 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7916337 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6448400 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
179533 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-6154683 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-293717 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6448400 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2050073 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-5871058 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12277 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
60707 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
122638 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
128018 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
213595 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
229868 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
415050 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
274302 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
352506 usd
us-gaap Operating Expenses
OperatingExpenses
543068 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-274302 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-352506 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-543068 usd
CY2024Q2 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CY2023Q2 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
356000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
0 usd
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
1 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
3378 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
4 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
3386 usd
CY2024Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
33900 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
46700 usd
CY2024Q2 us-gaap Other Noncash Expense
OtherNoncashExpense
19416 usd
CY2023Q2 us-gaap Other Noncash Expense
OtherNoncashExpense
18283 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
37699 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
36365 usd
CY2024Q2 us-gaap Accretion Expense
AccretionExpense
-0 usd
CY2023Q2 us-gaap Accretion Expense
AccretionExpense
2877 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39141 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
435248 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-293717 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19612 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-582209 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-377031 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2400 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-293717 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19612 usd
us-gaap Net Income Loss
NetIncomeLoss
-582209 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7236447 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8569113 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7236447 shares
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5469 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
19612 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4867 usd
us-gaap Net Income Loss
NetIncomeLoss
-582209 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-6448400 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10877 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-5253312 usd
us-gaap Net Income Loss
NetIncomeLoss
-582209 usd
us-gaap Net Income Loss
NetIncomeLoss
-379431 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4867 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10877 usd
CPMV Gain On Redemption Of Preferred Stock
GainOnRedemptionOfPreferredStock
-0 usd
CPMV Gain On Redemption Of Preferred Stock
GainOnRedemptionOfPreferredStock
433000 usd
CPMV Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
-0 usd
CPMV Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
46700 usd
CPMV Noncash Interest On Convertible Notes
NoncashInterestOnConvertibleNotes
36565 usd
CPMV Noncash Interest On Convertible Notes
NoncashInterestOnConvertibleNotes
36365 usd
CPMV Interest Expense On Loan Payable
InterestExpenseOnLoanPayable
1133 usd
CPMV Interest Expense On Loan Payable
InterestExpenseOnLoanPayable
0 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
us-gaap Accretion Expense
AccretionExpense
11473 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-14812 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34239 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
6562 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-2388 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
327566 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
427089 usd
CPMV Increase Decrease In Accrued Professional Fees
IncreaseDecreaseInAccruedProfessionalFees
0 usd
CPMV Increase Decrease In Accrued Professional Fees
IncreaseDecreaseInAccruedProfessionalFees
47020 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-18186 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
3781 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-207444 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-290675 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
0 usd
CPMV Proceeds From Redemption Of Preferred Stock Of Holocom
ProceedsFromRedemptionOfPreferredStockOfHolocom
433000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
433000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
55000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-152444 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
142325 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
156178 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220645 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3734 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
362970 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2400 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Nature Of Operations
NatureOfOperations
<p id="xdx_80B_eus-gaap--NatureOfOperations_zhSZUaH5elYe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>1.        <span id="xdx_827_zZUVehInvlr7">Organization and Business</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Organization</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mosaic ImmunoEngineering, Inc. (the “Company,” “Mosaic,” “we,” “us,” or “our”) is a corporation organized under Delaware law on March 24, 1992. We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidate and we are pursuing new product candidates and platforms to expand our pipeline based on a deep understanding of immunotherapies and our license agreements with University of California San Diego.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has two inactive wholly owned subsidiaries: Mosaic ImmunoEngineering Development Company, a corporation organized under Delaware law on March 30, 2020 and Patriot Data Solutions Group, Inc.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going Concern and Management’s Plans</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. At June 30, 2024, the Company had cash and cash equivalents of $<span id="xdx_90A_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pp0p0_c20240630_zWrNf8YyCuTk" title="Cash and cash equivalents">3,734</span> and has not yet generated any revenues. Therefore, our ability to continue our operations is highly dependent on our ability to raise capital to fund future operations. We anticipate, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy our operational and capital requirements through twelve months from the filing date of this Quarterly Report on Form 10-Q.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are a number of uncertainties associated with our ability to raise additional capital and we have no current arrangements with respect to any additional financing. In addition, the continuation of disruptions caused by COVID-19 or other variants or pandemics, broad-based inflation, and various economic indicators that the United States economy may be entering a recession in upcoming quarters may cause investors to slow down or delay their decision to deploy capital which will adversely impact our ability to fund future operations. Consequently, there can be no assurance that any additional financing on commercially reasonable terms, or at all, will be available when needed. The inability to obtain additional capital will delay our ability to conduct our business operations. Any additional equity financing may involve substantial dilution to our then existing stockholders. The above matters raise substantial doubt regarding our ability to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3734 usd
CY2023Q2 CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
356000 usd
CPMV Gain On Redemption Of Preferred Stock Of Holocom
GainOnRedemptionOfPreferredStockOfHolocom
433000 usd
CY2023Q2 CPMV Investment Owned Balance Shares Redeemed
InvestmentOwnedBalanceSharesRedeemed
1050000 shares
CPMV Investment Owned Balance Shares Redeemed
InvestmentOwnedBalanceSharesRedeemed
1242500 shares
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
623577 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
641763 usd
CY2024Q2 CPMV Convertible Notes Redemption Value
ConvertibleNotesRedemptionValue
1145790 usd
CY2024Q2 us-gaap Accretion Expense
AccretionExpense
0 usd
us-gaap Accretion Expense
AccretionExpense
1446 usd
CY2023Q2 us-gaap Accretion Expense
AccretionExpense
2877 usd
us-gaap Accretion Expense
AccretionExpense
11473 usd
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
5469 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4867 usd
us-gaap Share Based Compensation
ShareBasedCompensation
10877 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
0 usd
CY2024Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.16 pure
CY2024Q2 us-gaap Proceeds From Loans
ProceedsFromLoans
15000 usd
us-gaap Proceeds From Loans
ProceedsFromLoans
55000 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-005676-index-headers.html Edgar Link pending
0001683168-24-005676-index.html Edgar Link pending
0001683168-24-005676.txt Edgar Link pending
0001683168-24-005676-xbrl.zip Edgar Link pending
cpmv-20240630.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mosaic_ex3101.htm Edgar Link pending
mosaic_ex3102.htm Edgar Link pending
mosaic_ex3201.htm Edgar Link pending
mosaic_ex3202.htm Edgar Link pending
mosaic_i10q-063024.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
cpmv-20240630_lab.xml Edgar Link unprocessable
cpmv-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mosaic_i10q-063024_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cpmv-20240630_cal.xml Edgar Link unprocessable
cpmv-20240630_def.xml Edgar Link unprocessable